Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Next Previous
Trial Profile

A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 12 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QPI 1007 (Primary)
  • Indications Ischaemic optic neuropathy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Quark Pharmaceuticals

Most Recent Events

  • 01 Jan 2026 Primary endpoint has not been met. (Effect of QPI-1007 as assessed by Best Corrected Visual Acuity (BCVA)), according to results published in Ophthalmology.
  • 01 Jan 2026 Results assessing safety and efficacy of intravitreal injection of QPI-1007, a small interfering RNA against the apoptotic protein caspase 2, in participants with acute-onset NAION, published in the Ophthalmology.
  • 14 Jul 2019 This trial has been completed in Germany.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top